Article Details

LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe ...

Retrieved on: 2022-09-08 18:25:34

Tags for this article:

Click the tags to see associated articles and topics

LEO Pharma presents new AdbryTM (tralokinumab-ldrm) safety data in moderate-to-severe .... View article details on hiswai:

Excerpt

4. Adbry, a high-affinity human monoclonal antibody, was approved by the U.S. Food and Drug Administration (FDA) in December 2021 for the treatment ...

Article found on: www.valdostadailytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up